Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis drug tildrakizumab tested in everyday practice

NCT ID NCT04203693

Completed Disease control Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study followed 331 adults with moderate-to-severe plaque psoriasis who were treated with tildrakizumab (Ilumetri) as part of their routine care. Researchers tracked how much the skin cleared and how quality of life improved over up to two years. The goal was to see if the drug works as well in real life as it did in earlier clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tildrakizumab (Ilumetri)
What this could lead to
If successful, this study could confirm that tildrakizumab works well and is safe for long-term use in everyday medical practice for people with moderate-to-severe plaque psoriasis.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. It cannot prove cause and effect, and long-term safety data are still limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

  • Investigational Site 1

    Nice, France

  • Investigational Site 1

    Augsburg, Germany

  • Investigational Site 1

    Arezzo, Italy

  • Investigational Site 10

    Cologne, Germany

  • Investigational Site 10

    Roma, Italy

  • Investigational Site 11

    Lübeck, Germany

  • Investigational Site 11

    Roma, Italy

  • Investigational Site 12

    München, Germany

  • Investigational Site 12

    Rozzano, Italy

  • Investigational Site 13

    Merzig, Germany

  • Investigational Site 14

    Oberursel, Germany

  • Investigational Site 15

    Quedlinburg, Germany

  • Investigational Site 2

    Berlin, Germany

  • Investigational Site 2

    Brescia, Italy

  • Investigational Site 3

    Bochum, Germany

  • Investigational Site 3

    Catania, Italy

  • Investigational Site 4

    Erlangen, Germany

  • Investigational Site 4

    Florence, Italy

  • Investigational Site 5

    Greifswald, Germany

  • Investigational Site 5

    Genova, Italy

  • Investigational Site 6

    Hamburg, Germany

  • Investigational Site 6

    Lecce, Italy

  • Investigational Site 7

    Halle, Germany

  • Investigational Site 7

    Modena, Italy

  • Investigational Site 8

    Kiel, Germany

  • Investigational Site 8

    Roma, Italy

  • Investigational Site 9

    Kiel, Germany

  • Investigational Site 9

    Roma, Italy

  • Investigational site 1

    Breda, Netherlands

  • Investigator Site 1

    Baden, Austria

  • Investigator Site 1

    Brussels, Belgium

  • Investigator Site 2

    Vienna, Austria

  • Investigator Site 2

    Charleroi, Belgium

  • Investigator Site 2

    Poitiers, France

  • Investigator Site 3

    Genk, Belgium

  • Investigator Site 4

    Ghent, Belgium

  • Investigator Site 5

    Herstal, Belgium

  • Investigator Site 6

    Jette, Belgium

  • Investigator Site 7

    Lede, Belgium

  • Investigator Site 8

    Leuven, Belgium

  • Investigator Site 9

    Mons, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.